KP-302 (compound 23), a selective inhibitor of protein arginine deaminase PAD2 with a dissociation constant (Ki) of 60 μM, has demonstrated potential as a disease-modifying agent for multiple sclerosis (MS). In the EAE mouse model of MS, KP-302 not only reversed physical disability but also eliminated T cell infiltration in the brain .